LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
van Halsema, CL; Fielding, KL; Chihota, VN; Lewis, JJ; Churchyard, GJ; Grant, AD (2012)
Publisher: International Union Against Tuberculosis and Lung Disease
Languages: English
Types: Article
Subjects:
UNLABELLED: SETTING AND OBJECTIVE: To describe trends in drug-resistant tuberculosis (TB) in two gold-mining workforces, South Africa, 2002-2008. DESIGN: TB programme data analysis. RESULTS: TB case notification rates decreased between 2002 and 2008 from 4006 to 3018 per 100?000 and from 3192 to 2468/100?000 for Companies A and B, respectively. Human immunodeficiency virus (HIV) prevalence exceeded 80% in TB episodes with known status. The proportion of TB episodes with multidrug-resistant TB (MDR-TB) increased from 6/129 (4.7%) to 17/85 (20.0%) among previously treated cases, and from 4/38 (10.4%) to 7/28 (25.0%) in Companies A and B, respectively (tests for trend, Company A, P < 0.001; Company B, P = 0.304). Case notifications of MDR-TB increased during 2002-2008 from 39.8 to 122.9/100?000/year in Company A and from 7.8 to 96.8/100?000/year in Company B. Coverage of second-line drug susceptibility testing (DST) among MDR-TB episodes was low. Previous treatment exposure was a strong risk factor for MDR-TB (prevalence ratio 8.78, 95%CI 5.94-12.97 in previously treated vs. untreated individuals). CONCLUSION: Despite decreasing TB notifications overall, MDR-TB notifications and proportions of episodes with MDR-TB increased in the larger company. Cure must be ensured in first episodes to prevent acquired resistance. Improved coverage of culture, DST and HIV testing is required to allow treatment to be optimised.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Corbett EL, Churchyard GJ, Charalambous S, et al. Morbidity and mortality in South African gold miners; impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002;32(9):1251-1258
    • 2. World Health Organization. Global Tuberculosis Control: WHO Report 2010. World Health Organization, Geneva 2010. (WHO/HTM/TB/2010.07)
    • 3. Lewis JJ, Charalambous S, Day JH, et al. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 2009;180(12):1271-1278
    • 4. Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000; 14(17): 2759-2768
    • 5. Churchyard GJ, Corbett EL, Kleinschmidt I, Mulder D, De Cock KM. Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. Int J Tuberc Lung Dis 2000;4(5):433-440
    • 6. Murray J, Sonnenberg P, Shearer S, Godfrey-Faussett P. Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection. S Afr Med J 2000;90(4):381-386
    • 7. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368(9547):1575-1580
    • 8. Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010;16(2):264-271
    • 9. Fielding, KL, Grant AD, Hayes RJ, Chaisson RE, Corbett EL, Churchyard GJ. Thibela TB: Design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis among gold miners in South Africa. Contemp Clin Trials 2011;32(3):382-392
    • 10. World Health Organization 2008. Anti-tuberculosis drug resistance in the world: fourth global report. World Health Organization, Geneva, 2008. WHO/HTM/TB/2008.394
    • 11. Chudeya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampicin, ethambutol and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009;48:1685-1694
    • 12. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011;204 (12);1951-1959
    • 13. Godfrey-Faussett P, Sonnenberg P, Shearer SC, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000;356(9235):1066-1071
    • 14. Van Rie A, Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet 2000;356(9223):22-25
    • 15. Weyer K, Lancaster J, Brand J, van der Walt M, Levin J. Survey of Tuberculosis Drug Resistance in South Africa 2001-2002. MRC South Africa 2004. Available at http://www.sahealthinfo.org/tb/tbsurvey.htm . Accessed 7th February 2011.
    • 16. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 2009;4(5):e5561 doi 10.1371/journal.pone.0005561
    • 17. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23(13):1717-1725
    • 18. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362(8):697-706
    • 19. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Eng J Med 2011;365(16):1471-1481
    • 20. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Eng J Med 2011;365(16):1482-1491
    • 21. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. World Health Organization, Geneva 2010.
    • 22. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in southern Africa. PLoS One 2009;4(9):e7186. Doi:10.1371/journal.pone.0007186
    • 23. Hassim S, Shaw PA, Sangweni P, et al. Detection of a substantial rate of multidrugresistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples. Clin Infect Dis 2010;50:1053-1059
    • 24. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Resp Crit Care Med 2009;181:80-86
    • 26. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006;12:744-51
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

  • NIH | Extensively Drug-Resistant ...
  • NIH | South Africa Tuberculosis A...

Cite this article